CDR-Life Inc doses first patient in phase 1 trial of BI 771716

(Image Credit: AdobeStock/MargJohnsonVA)

CDR-Life Inc announced the first patient has been dosed in its Phase 1 trial (NCT06006585) of BI 771716 for the treatment of geographic atrophy (GA).

According to a press release from CDR-Life, BI 771716 is licensed to Boehringer Ingelheim and is a “highly specific antibody fragment of reduced size enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.”¹

Christian Leisner, PhD, Chief Executive Officer at CDR-Life, commented on the initiation of the trial in the press release from the company.

“This milestone marks CDR-Life's emergence as a clinical-stage company and underscores the ability of our platform to generate molecules that may one day bring life-changing treatments to patients,” said Leisner. “We look forward to the continued development of BI 771716 as it progresses through the clinic.”¹

The Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of intravitreal single-rising doses and multiple doses of BI 771716 as a potential treatment for GA.¹

References:

1. CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy. Press release. Released December 6, 2023. Accessed December 7, 2023. https://www.globenewswire.com/news-release/2023/12/06/2791553/0/en/CDR-Life-Announces-First-Patient-Dosed-in-Phase-1-Study-with-Boehringer-Ingelheim-Evaluating-Potential-Treatment-for-Geographic-Atrophy.html